Skip to main content
LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.
Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia.
Three-year results from phase 1 of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia
The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.
A new target for fetal hemoglobin reactivation.
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.
Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.